Announcement PDF Not for release to US Wire Services or distribution in the United States Capital Raising Presentation October 2024 ampliatx.com | @ampliatx 1 IMPORTANT INFORMATION This presentation (Presentation) has been prepared by Amplia Therapeutics Limited ACN 165 160 841 (the Company or Amplia) and Future performance and forward-looking statements: This Presentation contains certain references to forecasts, estimates, assumptions and is dated 30 October 2024. This Presentation has been prepared in relation to a proposed capital raising comprising a placement to other forward-looking statements and statements regarding the intent, belief or current expectations of Amplia. The words “likely”, “expect”, sophisticated and professional investors (Placement) and a pro-rata accelerated non-renounceable entitlement offer to eligible “aim”, “should”, “could”, “may”, “anticipate”, “predict”, “believe”, “plan” and other similar expressions are intended to identify forward-looking shareholders (Entitlement Offer) of new ordinary fully paid shares in Amplia (New Shares) (together referred to as the Offer). statements. Participants in the Offer will be entitled to subscribe for 3 options (Attaching Options) for every 4 New Shares subscribed for. The Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject Attaching Options will have an exercise price of $0.1725 and will expire on 31 October 2027. The offer of Attaching Options to to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. participants in the Placement is subject to shareholder approval for the purposes of ASX Listing Rule 7.1. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future The Entitlement Offer (including the offer of Attaching Options) and the offer of Attaching Options to participants in the Placement will performance. This Presentation contains such statements, which are subject to risk factors associated with an investment in Amplia. The be undertaken pursuant to a transaction-specific prospectus dated 30 October 2024. Company believes that these statements are reasonable, but they may be affected by a range of variables which could cause actual results or Summary Information: This Presentation contains summary information about Amplia and its activities as at the date of this trends to differ materially. Forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important Presentation. The information in this Presentation is of a general nature and does not purport to be complete or comprise all factors that could cause actual results, performance or achievements of Amplia to be materially different from future results, performances or information which a shareholder or potential investor may require in order to determine whether to deal in Amplia shares or that achievements expressed or implied by such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations which speak only as of the date of this Presentation. Act 2001 (Cth). It should be read in conjunction with Amplia’s other periodic and continuous disclosure announcements lodged with the Market and industry data: This Presentation contains data relating to the industries, segments and markets in which the Company operates Australian Securities Exchange, which are available at www.asx.com.au. (Industry Data). Unless otherwise stated, this information has been prepared by the Company using both publicly available data and its own Restrictions: This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the internally generated data. The Company’s internally generated data is based on estimates and assumptions that the directors and management United States or in any jurisdiction in which such offer would be illegal. Any securities offered in connection with this Presentation have of the Company believe are reasonable. In addition to the Industry Data, the Presentation contains third party market data, estimates and not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (US Securities Act) or the securities laws of any projections. There is no assurance regarding the accuracy of such information and the third party information, and the Industry Data, has not state or other jurisdiction of the United States, and may not be offered or sold in the United States except in transactions exempt from, been independently verified by the Company. or not subject to, registration under the US Securities Act and applicable US state securities laws. This Presentation may not be Financial Information: All financial information disclosed in this Presentation is presented in Australian dollars unless otherwise noted and is distributed in the United States, or any other jurisdiction, except in accordance with the legal requirements applicable in such jurisdiction. The distribution of this Presentation outside Australia may be restricted by law, and persons into whose possession this Presentation comes should observe any such restrictions. Any failure to comply with such restrictions may violate applicable securities laws. Please refer to the international offer restrictions section of this Presentation. Presentations are tools that can Disclaimer: No representation or warranty, express or implied, isbe madeused as to the fairness or correctness of the information, opinions and as lectures, speeches based on financial information disclosed to ASX. Any discrepancies between totals and sums of components in tables and figures contained in this Presentation are due to rounding. conclusions contained in this Presentation. To the maximum extent permitted by law, each of Taylor Collison Limited and Bell Potter Securities Not financial product advice: This Presentation does not, and does not purport to, contain all information necessary to make an Limited (JLMs) and Amplia and their respective officers, directors, employees, agents and advisers: (1) disclaim all responsibility and liability investment decision, is not intended as investment or financial advice (nor tax, accounting or legal advice) and must not be relied upon (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or as such. This Presentation does not take into account the investment objectives, financial situation or needs of any particular investor. reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation; (2) disclaim any obligation or Investors are encouraged to seek independent professional advice when deciding if an investment in the Company is appropriate. The undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions; and Company is not licensed to provide financial product advice in respect of its own securities. This Presentation is not a prospectus, (3) do not make any representation or warranty, express or implied, as to the accuracy, reliability, completeness of the information in this product disclosure statement or other offering document under Australian law (or any other law). It is not, and does not constitute, an Presentation or that this Presentation contains all material information about Amplia or that a prospective investor or purchaser may require in invitation or offer of securities for subscription, purchase or sale in any jurisdiction. evaluating a possible investment in Amplia or acquisition of shares, or the likelihood of fulfilment of any forward-looking statement. The JLMs and Investment risk and past performance: An investment in Amplia shares is subject to known and unknown risks, some of which are their advisers, affiliates, related bodies corporate, directors, officers, employees and agents (JLM Parties) make no recommendations as to beyond the control of the Company and its directors. The Company does not guarantee any particular rate of return or the whether you should participate in the Offer nor do they make any representations or warranties to you concerning the Offer, and you represent, performance of Amplia. Past performance is not, and should not be relied on as being, indicative of future performance. Investors warrant and agree that you have not relied on any statements made by the JLM Parties in relation to the Offer and you expressly disclaim any should have regard to the ‘Risks’ section of this Presentation. fiduciary duty with any of them. 2 EXECUTIVE SUMMARY Best-in-class FAK inhibitor in development with near term clinical milestones Developing a pipeline of small molecule inhibitors of FAK – a validated cancer target • Lead compound narmafotinib is the best-in-class Focal Adhesion Kinase (FAK) inhibitor in development • Promising clinical safety and tolerability positions narmafotinib as the preferred agent to enhance activity of drugs for treatment of pancreatic cancer and other solid tumours • Phase 1b trial in pancreatic cancer showed preliminary signs of efficacy with duration on trial significantly improved vs current standard of care (gemcitabine and Abraxane®) • Compelling pre-clinical data in ovarian cancer, IPF and other solid tumours Phase 2a ACCENT clinical trial in pancreatic cancer underway with activity threshold already achieved • Completed enrolment of first 26 patients and recruitment of remaining 24 patients underway • Achieved activity threshold of 6 confirmed partial responses (PRs) allowing recruitment of full 50 patients. Drug well tolerated and promising signs of efficacy • Trial recruitment expected to complete Q1 2025 with topline data expected Q3 2025 Preparing for narmafotinib trial in pancreatic cancer in the US • Clearance of IND application for clinical study of narmafotinib in combination with FOLFIRINOX (standard-of-care therapy for advanced pancreatic cancer in US) • Targeting commencement of dose escalation trial in 1H 2025 Orphan Drug and Fast Track Designations granted by US FDA • Provides 7 years market exclusivity in US • Receive tax credits for clinical costs and exemptions from certain fees • Expedited review of documentation • Eligible for Accelerated Approval and Priority Review Voucher Capital raising of up to approximately A$13.0m to fund the clinical program • Undertaking a capital raising of up to approximately $13.0 million via a Placement, Director Placement and Entitlement Offer at an offer price of $0.115 per New Share • Funds raised will be used to complete the Phase 2a ACCENT trial, US FOLFIRINOX dose escalation study, CMC manufacturing for follow on studies, additional preclinical work and costs of the Offer 3 COMPANY SUMMARY ASX:ATX (29-Oct-2024) Shares on issue A$0.135 12 $0.20 10 $0.16 274.8m Millions Share price 12 month share price chart 8 $0.12 Market cap (29-Oct-2024) Cash (30-Sep-2024) A$37.1M Shareholders $0.08 4 A$4.6M • Platinum Investment Substantial 6 Management Ltd (12.9%) • Blueflag Holdings Pty Ltd (6.9%) $0.04 2 $Oct23 Dec23 Feb24 Apr24 Market Volume Jun24 Aug24 0 Oct24 Close Price • Acorn Capital Ltd (5.8%) • Pengana Capital (4.3%) • Board + Management (5.8%) 4 EXPERIENCED BOARD + MANAGEMENT BOARD MANAGEMENT Rhiannon Jones PhD GAICD COO Warwick Tong Robert Peach Jane Bell Chris Burns* MB ChB MPP GAICD Chair PhD Director LLB, LLM (Lond), FAICD Director PhD GAICD CEO and MD Terrie-Anne Cock PhD Director Translational Science Charlotte Mulder BVSc (Hons) MBA Director Early Clinical Development Adrian Sulistio * Co-recipient of 2024 PM’s Prize for Innovation B Eng (Hons), B Com, PhD Manager Product Development 5 PIPELINE 6 Amplia’s drugs inhibit the enzyme Focal Adhesion Kinase (FAK) 7 FOCAL ADHESION KINASE (FAK) FAK is a critical protein in cancer growth and spread, and in formation of fibrotic (scar) tissue Amplia’s drugs potently and selectively block the activity of the FAK protein Broad clinical potential Cancer Fibrosis Scarring 8 FAK INHIBITION IN CANCER FAK over-expressed and over-active in many cancers Higher FAK levels correlate with worse patient outcomes Multi-action of narmafotinib Anti-proliferative Reduces cells’ ability to proliferate and migrate Narmafotinib potently inhibits FAK and thereby reduces cancer growth Synergy with chemotherapies Enhances activity of drugs and other therapies Tumour (blue - cancer cells; green- fibroblasts; purple, grey and yellow - suppressive immune cells) • within cancer cell • in tumour microenvironment Narmafotinib blocks critical pathways supporting tumour growth Anti-fibrotic Reduces scar-tissue in TME*, improving permeability to drugs Immunomodulatory Improves immune cell reactivity to tumour cells *Tumour Microenvironment 9 FAK INHIBITORS IN DEVELOPMENT Only 3 companies with bona fide FAK inhibitors in development Verastem (VSTM.NASDAQ, Mkt Cap US$136m (A$207m)) Verastem Inxmed • Co-development with a second drug (avutometinib) • Promising data in low-grade serous ovarian cancer (~10% patients) • New Drug Application (NDA) with FDA reported as imminent • Higher adverse events with drug combination* • Completed Phase 2 trials; Phase 3 underway Inxmed (private) Amplia • Promising early data in high-grade serous ovarian cancer study • High percentage patients on trial presenting with high protein in urine† possibly indicating off-target drug effect to kidneys • Phase 2 studies underway Narmafotinib has an excellent selectivity profile, improved pharmacokinetics and good tolerability in patients * J. Clin. Oncol. 2024; 42 (16)_suppl_4140 † J. Clin. Oncol. 2024; 42 (16)_suppl_8605 10 Clinical studies of narmafotinib in pancreatic cancer 11 PANCREATIC CANCER 13% Increasing Prevalence 5 year survival Market size Estimated 66,440 diagnoses and 51,750 deaths in US this year* Difficult-to-treat: typically detected late in disease progression** Global treatment market estimated at ~US$2.5 billon † in 2024 ~4,506 diagnoses in AU in 2023** * American Cancer Society: https://cancerstatisticscenter.cancer.org/) ** Cancer Australia: https://www.canceraustralia.gov.au/cancer-types/pancreaticcancer/statistics Projected to grow to † ~US$12.6 billion by 2037 † Research Nester: https://www.researchnester.com/reports/pancreaticcancer-market/5299 12 ACCENT PANCREATIC TRIAL Background FAK activity correlates with worse outcome • Fibrosis features within TME,‡ consistent with activated FAK , correlate with worse patient outcome • Patients with reduced FAK activity in tumour have improved probability of survival Efficacy with FAK inhibition in preclinical studies • Narmafotinib decreases tumour fibrosis (collagen) • Narmafotinib treatment improves survival in disease models Low levels active FAK = better survival High levels active FAK = worse survival EMBO Mol Med 2020, 12, e12010 • FAK inhibition synergises with SOC* chemotherapies and targeted therapies ‡ Tumour microenvironment * Standard-of-care 13 ACCENT PANCREATIC TRIAL FDA Interactions Orphan Drug Designation* granted • Assistance with development planning • Tax credits for clinical costs • Exemptions from certain fees • Seven years of post-approval marketing exclusivity Fast Track Designation ‡ granted • Increased engagement with FDA • Expedited review of documentation • Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met Clearance of Investigational New Drug application • Clinical study of narmafotinib in combination with FOLFIRINOX chemotherapy now possible in the US • FOLFIRINOX standard-of-care therapy for advanced Pancreatic Cancer in US • Preclinical studies indicate narmafotinib improves activity of FOLFIRINOX in mouse models * www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designatingorphan-product-drugs-and-biological-products ‡ https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approvalpriority-review/fast-track Mice bearing human pancreatic cancer cells show improved survival when treated with combination of narmafotinib and FOLFIRINOX, compared to FOLFIRINOX alone. 14 ACCENT PANCREATIC TRIAL Background 2021 Healthy Volunteer trial demonstrated excellent clinical profile Narmafotinib safe and well tolerated Narmafotinib circulating levels over time • No withdrawals or safety trends Excellent Pharmacokinetics • Once-a-day oral dosing • No impact of food on drug absorption Inhibition of FAK demonstrated in skin tissue Narmafotinib predicted to be safe for co-dosing with other drugs 15 ACCENT TRIAL DESIGN An open-label trial of narmafotinib in combination with gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer Trial Read-outs: Phase 1b: Primary endpoint – Safety and Tolerability; Secondary endpoint – PK and preliminary efficacy Phase 2a: Primary endpoint – Objective Response Rate; Secondary endpoint – Duration on Trial Dose Selected Phase 1b (Australia) Phase 2a (Australia and South Korea) 26 patients 14 patients Interim Analysis ≥6 PR Phase 2a (cont) (Australia and South Korea) 24 patients 400 mg* 200 mg 100 mg COMPLETED RECRUITED UNDERWAY *Dose selected for Phase 2 16 Phase 1b data indicates narmafotinib well tolerated with preliminary signs of efficacy 17 ACCENT PHASE 1b SUMMARY Narmafotinib safe and well tolerated • All 14 patients elected to stay on drug post cycle 1 • One DLT*: nausea >72 hours • Fatigue (Grade 3 or below) in more than 1 patient likely drug related Three dose levels examined, with 400 mg dose (oral, once-a-day) in days preceding chemotherapy identified as appropriate for Phase 2a study Data suggests % response and duration on trial is dose dependent with 4/6 patients on top dose recording confirmed PRs† • One patient at 400 mg dose remains on study (>12 months) * Dose Limiting Toxicity † Partial Responses 18 Preliminary Phase 2a data also positive 19 ACCENT PHASE 2a Preliminary Data Narmafotinib continues to be generally well tolerated in this patient group with no dose reductions 6 confirmed PRs observed at 4 month timepoint by end Sep 2024 • >30% reduction in tumour lesion size sustained over 2 months • No new lesions Developing data-set sufficiently positive, compared to historical data, to continue trial and complete recruitment of 50 patients 20 ACCENT PHASE 2a Preliminary Data Duration on Trial* High-level data as of 27 September 2024* Trial is ongoing - dataset is developing • 15 patients remain on study more months) • 4 PRs yet to be confirmed • 7 SDs for 2 or more months • 8 patients whose disease has progressed Individual patients • 6 confirmed PRs (= PR sustained over 2 or • 3 patients that have withdrawn or were considered ineligible for assessment Days on trial *Based on data available in trial database on Sep 27; responses are investigator read; analysis may change as data matures. PR = Partial response, SD = Stable Disease 21 ACCENT PHASE 2a Preliminary Data Collated data of ‘best response’ at any scan Best Response (evaluable patients)* indicates promising activity • 19 patients have recorded a decrease in tumour size • 12 patients have recorded a decrease in tumour size >30% Partial Response Stable Disease Progressive Disease *Based on data available in trial database on Sep 27; responses are investigator read; analysis may change as data matures. 22 ACCENT PHASE 2a Preliminary Data Comparison with historical gemcitabine/ Abraxane data indicates promising response trends, noting • Different data-set sizes • ACCENT trial still ongoing – 15 patients remain on trial Response ACCENT Phase 2a Historical Part A* MPACT Trial Best Response Best Overall Response** Classification (n=26) Complete Response (CR) 0 (0%) <1% Partial Response (PR) 12 (46%)† 23% Stable Disease (SD) 8 (31%) 27% Progressive Disease (PD) 3 (12%) 20% Not evaluable (NE) 3 (12%)‡ 30% Median Duration on Treatment 136 days 117 days *_Based on data available in trial database on Sep 27; responses are investigator read; analysis may change as data matures ** Confirmed data from MPACT trial (independent review); NEJM 2013: 369; 1691-1703 † Partial response as best response includes 6 confirmed PRs, 4 unconfirmed PRs, 2 PRs that converted to PD ‡ Includes one patient who withdrew (n=431) 23 ACCENT PHASE 2a Preliminary Data Comparison with historical gemcitabine/ Abraxane data suggests combination with ACCENT Phase 2a Response over time (all lesions)* • Faster response • Longer/sustained response Historical gemcitabine/Abraxane data‡ Pancreatic lesions Mean % Change from Baseline ± 95% CI (all target lesions) narmafotinib leads to: Metastatic lesions Time on trial (weeks) 0 8 Time on trial (weeks) 16 ‡ Pancreas 2017: 46; 203 *Based on data available in trial database on Sep 27; responses are investigator read; analysis may change as data matures. 24 Positioning narmafotinib as the preferred agent to enhance activity of drugs for solid tumours 25 FOLFIRINOX COMBINATION STUDY Narmafotinib + FOLFIRINOX in advanced pancreatic cancer Daily dosing of narmafotinib + fortnightly mFOLFIRINOX* • First-line therapy/newly diagnosed patients • Cleared IND from FDA for US-based trial • Open label study in 2 parts • Part A: (i) Dose escalation; (ii) Identification of RP2D† to Project Optimus‡ guidance • Part B: Safety and efficacy at RP2D Part A (i) – estimated 20 patients • Funding for this stage included in use-of-funds • Drug product already in-hand Part A (ii) – estimated 40 patients • Drug substance costs for this stage included in use-of-funds Part B – estimated 100 patients • No costs for this stage currently sought Part A Stage (i): - 3+3 or BOIN design; estimate ~20 patients - Safety, PK, PD Dose 4 Dose 3 Dose 2 Dose 1 Stage (ii): - ~20 patients per cohort - Safety and efficacy MTD§ from (i) Dose below MTD * Modified FOLFIRINOX † Recommended Phase 2 Dose ‡_www.fda.gov/about-fda/oncology-center-excellence/project-optimus § Maximum tolerated dose 26 OVARIAN CANCER OPPORTUNITY Narmafotinib + SOC* therapy in resistant ovarian cancer Strong FAK involvement in ovarian cancer Tumour Burden • FAK is overexpressed in ovarian cancer • FAK levels increase post-chemotherapy • FAK activity drives tumour growth and resistance to therapies Promising preclinical data with narmafotinib • Demonstrated activity against ovarian cancer cells in vitro and in vivo Significant interest from clinicians in Australia and US in our program • Positive clinical data from ovarian cancer studies by competitors Verastem (in LGSOC‡) and Inxmed (in HGSOC†) further justify clinical work in this space Mice bearing mouse ovarian cancer cells show minimal tumour growth (measured as flux) when treated with narmafotinib while standard-of-care drug niraparib is largely ineffective. * Standard of care ‡ Low Grade Serous Ovarian Cancer † High Grade Serous Ovarian Cancer 27 FUTURE MILESTONES 2024 Pancreatic Cancer Ovarian Cancer Partnering 2025 ACCENT Interim Analysis Commence FOLFIRINOX Trial in US ACCENT Topline Data ACCENT Trial Fully Recruited Commence Clinical Trial (subject to funding) Regional Licensing Deal 28 OPPORTUNITY SUMMARY Combinations in pancreatic cancer Combinations in ovarian cancer Preclinical evidence in other solid tumors Gemcitabine and Abraxane (ACCENT trial) FOLFIRINOX (US trial with open IND*) Platinum resistant disease Maintenance therapy post surgery Bile duct, oesophageal, head and neck cancer kRAS-mutant cancers (e.g. lung, colorectal) Other fibrotic cancers (e.g. liver cancer) * Investigational New Drug 29 Capital Raising Overview 30 CAPITAL RAISING OVERVIEW • Amplia is undertaking a capital raising (the “Offer”) of up to approximately A$13.0m comprising: - a 1 for 6.45 pro-rata accelerated non-renounceable entitlement offer to eligible Amplia shareholders to raise up to approximately A$4.9 million (“Entitlement Offer”); Offer Structure - an institutional placement (“Placement”) to raise up to approximately A$7.8m million utilising Amplia’s existing placement capacity under Listing Rules 7.1 and 7.1A; and - a placement to Amplia’s Directors to raise a total of $0.32 million, subject to shareholder approval. • Up to approximately 113.2 million new fully paid ordinary shares in Amplia (“New Shares”) to be issued under the Offer, representing approximately 41.2% of Amplia’s current shares on issue. • New Shares issued under the Offer will be issued at a price of A$0.115 (11.5 cents) per New Share (“Offer Price”), representing a: - 14.8% discount to the last close price on 29 October 2024 of $0.135; Offer Price - 18.6% discount to 5 trading day VWAP on 29 October 2024 of $0.141; and - 22.3% discount to 10 trading day VWAP on 29 October 2024 of $0.148. Institutional Offer Retail Offer Attaching Options • The institutional component of the Entitlement Offer (“Institutional Entitlement Offer”) and the Placement will be conducted by way of a bookbuild process on Wednesday, 30 October 2024. • Entitlements under the Institutional Entitlement Offer that are not taken up and entitlements of ineligible institutional shareholders will also be offered in the bookbuild process. • The retail component of the Entitlement Offer (“Retail Entitlement Offer”) is expected to open on Wednesday, 6 November 2024 and close at 5.00pm on Friday, 22 November 2024. • Eligible existing retail shareholders in Australia and New Zealand will have the opportunity to apply for additional New Shares under a ‘Top up Facility’. • New Shares will be offered under the Placement, Director Placement and Entitlement Offer with three (3) free attaching options for every four (4) New Shares issued (“Attaching Options”). • The Attaching Options will have an exercise price of $0.1725 and will expire on 31 October 2027. • Amplia will apply for quotation of the Attaching Options on the ASX. Quotation of the Attaching Options is subject to the Company satisfying ASX’s quotation requirements. • The offer of Attaching Options to Placement participants is conditional on Amplia shareholder approval at a General Meeting to be held on or around Monday, 9 December 2024. • Amplia’s directors have committed to subscribe for $325,000 worth of New Shares pursuant to the Director Placement, as follows (subject to shareholder approval): Director Placement - Dr Warwick Tong- $80,000 worth of New Shares (being 695,6215 New Shares and 521,739 Attaching Options); - Ms Jane Bell - $80,000 worth of New Shares (being 695,6215 New Shares and 521,739 Attaching Options); - Dr Robert Peach - $125,000 worth of New Shares (being 1,086,957 New Shares and 815,218 Attaching Options); and - Dr Chris Burns - $40,000 worth of New Shares (being 347,826 New Shares and 260,869 Attaching Options). Record Date • The record date for the Entitlement Offer is 7.00pm (Sydney, Australia time) on Friday, 1 November 2024. Prospectus • The Entitlement Offer and the offer of Attaching Options to Placement participants will be undertaken pursuant to a transaction-specific prospectus dated Wednesday, 30 October 2024. Ranking • All New Shares issued under the Offer will rank equally with existing Amplia shares from the date of issue (save that the New Shares offered under the Offer will be issued with Attaching Options). • Bell Potter Securities Limited (“Bell Potter”) and Taylor Collison Limited (“Taylor Collison”) are acting as Joint Lead Managers and Bookrunners to the Offer. The Offer is not underwritten. Joint Lead Managers 31 SOURCES AND USE OF FUNDS SOURCES OF FUNDS AMOUNT (A$M) Cash Balance 1 Anticipated R&D Rebate Capital Raising Proceeds Total Sources $4.6 2 3 $4.0 $13.0 $21.6 1 Cash balance as at 30 Sep 2024. 2 Subject to approval – see ‘R&D Tax Rebate’ in the Key Risks section below. 3 Assumes that the Offer is fully subscribed (before Offer costs) – see ‘Risks associated with the Offer’ in the Key Risks section below. PURPOSE AMOUNT (A$M) ACCENT • Trial Costs $5.9 FOLFIRINOX • Trial Costs • Shipping • PK/PD $6.3 CMC (Follow-on studies) $1.9 Operations, Pre-clinical, Working Capital $6.7 Offer Costs $0.8 Total Uses $21.6 32 OFFER TIMETABLE The timetable is indicative only and dates and times are subject to change without notice. Trading halt and announcement of Offer Prospectus lodged with ASIC and released to ASX Wednesday, 30 October 2024 Placement & Institutional Entitlement Offer opens Wednesday, 30 October 2024 Placement & Institutional Entitlement Offer closes Thursday, 31 October 2024 Announcement of results of Placement and Institutional Entitlement Offer and trading halt lifted Friday, 1 November 2024 Record date for Entitlement Offer (7.00pm Sydney time) Friday, 1 November 2024 Settlement of New Shares issued under the Placement and Institutional Entitlement Offer Wednesday, 6 November 2024 Entitlement and acceptance forms made available to Eligible Shareholders and Retail Entitlement Offer opens Wednesday, 6 November 2024 Issue of New Shares under the Placement and Institutional Entitlement Offer and Attaching Options under the Entitlement Offer Thursday, 7 November 2024 Retail Entitlement Offer closes (5.00pm Sydney time) Friday, 22 November 2024 Announcement of results of Retail Entitlement Offer Wednesday, 27 November 2024 Settlement of Retail Entitlement Offer Thursday, 2